XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present the
following posters at the 65th Annual Meeting of the American
Academy of Neurology in San Diego, California:
AP (arbaclofen placarbil)
Spasticity
-
An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and
Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due
to Multiple Sclerosis
Session Info: Poster Session P03: March 19,
2:00 pm - 6:30 pm PT
Poster #: P03.267
-
The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs
and Requirement for Non-Professional Care: Results of a
Cross-Sectional Study in the USA
Session Info: Poster Session
P03: March 19, 2:00 pm - 6:30 pm PT
Poster #: P03.217
-
Impact of Spasticity on Healthcare Resource Utilisation: Results of a
Cross-Sectional Study in the USA
Session Info: Poster Session
P03: March 19, 2:00 pm - 6:30 pm PT
Poster #: P03.211
XP1279
Parkinson’s Disease
-
Double-Blind Study of an Actively-Transported Levodopa Prodrug,
XP21279, in Parkinson Disease
Session Info: Poster Session P02:
March 19, 7:30 am – 12:00 pm PT
Poster #: P02.075
XP23829
Preclinical and Phase 1
Studies
-
Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl
Fumarate (DMF) and XP23829 in Rat and Monkey
Session Info: Poster
Session P01: March 18, 2:00 pm - 6:30 pm PT
Poster #: P01.159
-
Favorable Metabolism and Pharmacokinetics of Formulations of XP32829,
a Novel Fumaric Acid Ester, in Healthy Subjects
Session Info:
Poster Session P05: March 20, 2:00 pm – 7:00 pm PT
Poster #:
P05.189
About XenoPort
XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. Horizant®
(gabapentin enacarbil) Extended Release Tablets is our first
approved product in the United States. GlaxoSmithKline holds
commercialization rights for Horizant in the United States during
a transition period ending on April 30, 2013, following which XenoPort
will be responsible for the further development, manufacturing and
commercialization of Horizant. Regnite® (gabapentin enacarbil)
Extended-Release Tablets is approved and is being marketed in Japan.
Astellas Pharma Inc. holds all development and commercialization rights
for Regnite in Japan and five other Asian countries. XenoPort
holds all other world-wide rights to gabapentin enacarbil. XenoPort's
pipeline of product candidates includes potential treatments for
patients with spasticity, Parkinson's disease, relapsing-remitting
multiple sclerosis and/or psoriasis.
To learn more about XenoPort, please visit the web site at www.XenoPort.com.
Horizant, Regnite and XENOPORT are registered trademarks
of XenoPort, Inc.
Source code: XNPT2C
